Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Sakaguchi, Masakiyo

Class:IdPerson:9650834
_displayNameSakaguchi, Masakiyo
_timestamp2019-06-24 10:42:59
created[InstanceEdit:9650845] Orlic-Milacic, Marija, 2019-06-24
firstnameMasakiyo
initialM
surnameSakaguchi
(author)[LiteratureReference:9650832] Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
[LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations
[Change default viewing format]
No pathways have been reviewed or authored by Sakaguchi, Masakiyo (9650834)